Switzerland · Delayed Price · Currency is CHF Galderma Group AG Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 net sales rose 25.5% year-over-year to $1.473 billion, with double-digit growth across all segments and geographies. Full-year guidance for 17%-20% net sales growth and ~26% EBITDA margin is confirmed, supported by strong Dermatological Skincare and NEMLUVIO performance.
Fiscal Year 2025
-
Record net sales and profitability were achieved, driven by innovation and strong execution across all segments. 2026 guidance calls for double-digit growth and margin expansion, with Nemluvio's peak sales outlook doubled and break-even expected a year early.
-
Record net sales of $3.7B for the first nine months, up 15% year-on-year, with Q3 growth accelerating to 21%. Full-year guidance for net sales and EBITDA margin was raised, driven by strong performance in Nimluvio, neuromodulators, and skincare, with broad-based growth across geographies.
-
Record H1 2025 net sales of $2.45B (+12.2% y/y) driven by Nemluvio and Relfydess launches, with strong growth across all segments and geographies. Raised full-year sales guidance to 12%-14% and confirmed 23% EBITDA margin, while maintaining disciplined capital allocation and managing risks from tariffs and pricing pressures.
-
Record Q1 net sales of $1.129 billion, up 8.3% year-on-year, driven by strong launches and execution. Full-year guidance for 10%-12% net sales growth and 23% core EBITDA margin is confirmed, with tariff risks deemed manageable and international markets leading growth.
Fiscal Year 2024
-
Record 2024 results with $4.4B net sales (+9.3% YoY) and Core EBITDA over $1B, driven by strong international growth, innovation, and successful launches of Nemluvio and Relfydess. 2025 guidance targets 10–12% sales growth and 23% Core EBITDA margin, with continued investment in launches.
-
Record net sales of $3.3B and 9.2% year-on-year growth were driven by strong international and product category performance, with injectable aesthetics and dermatological skincare leading. Guidance for full-year net sales growth was narrowed to 8.8%-9.5%, and Core EBITDA margin is expected to match 2023.
-
A new scientific partnership and minority shareholding by L'Oréal aims to accelerate innovation in dermatology, leveraging both companies' complementary strengths while maintaining strategic independence and competitive positioning. The R&D collaboration is in early stages, with project details yet to be finalized.
-
Record H1 2024 net sales of $2.2B (+10.8% y/y) and core EBITDA of $514M (+17.7% y/y) were driven by strong growth in injectable aesthetics, skincare, and international markets. Full-year sales guidance was raised to the upper end of the 7%-10% range, with leverage and profitability improving.